Drug intelligence / Profile preview

UHE-103A1B

Development stage: Unknown
Lead developer: Therapeutics
Modality: Small Molecules
Administration: Topical

Overview

**UHE-103A1B** is an investigational topical fixed-dose combination cream developed by Therapeutics for **moccasin-type tinea pedis**. It combines a low-concentration antifungal component designated A1 with a keratolytic component designated B. The antifungal component is intended to eradicate dermatophyte infection, while the keratolytic component is intended to reduce plantar hyperkeratosis and improve treatment access through thickened stratum corneum. UHE-103A1B was evaluated as one arm of a completed Phase 2 randomized trial in moccasin-type tinea pedis.

Beyond the preview

Go deeper on UHE-103A1B.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on UHE-103A1B.

Explore the full profile